EUVIMEDEUVIMED entdecken
Crossref

A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative

Michael E Jacobson iD, Jonathan W Rick, Louise A A Gerbens, Wenelia Baghoomian, Lisa J Gould, Angelo V Marzano, Diana M Chen, Debbie L Oakes, Joachim Dissemond, Toshiyuki Yamamoto, Kanade Shinkai, Barbara Nolan und 4 weitere

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljad420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Michael E Jacobson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oregon Health and Science University, Portland, OR, USA. Hauptthemen laut MEDLINE: Pyoderma Gangrenosum. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pyoderma gangrenosum (PG) is a rare ulcerative skin condition with no current standardized outcomes or outcome measures. With a rich investigational therapeutic pipeline, standardization of outcomes and improvement of data quality and interpretability will promote the appropriate and consistent evaluation of potential new therapies. Core outcome sets (COS) are agreed, standardized sets of outcomes that represent the minimum that should be measured and reported in all clinical trials of a specific condition.

Objectives

To identify and reach a consensus on which domains (what to be measured) should be included in the Understanding Pyoderma Gangrenosum: Review and Analysis of Disease Effects (UPGRADE) core domain set for clinical trials in PG.

Methods

Collaborative discussions between patients and PG experts, and a systematic review of the literature identified items and prospective domains. A three-round international eDelphi exercise was performed to prioritize the domains and refine the provisional items (consensus: ≥ 70% of participants rating a domain as ‘extremely important’ and < 15% of participants voting ‘not important’), followed by an international meeting to reach consensus on the core domain set (consensus: < 30% disagreement). Item-generation discussions and consensus meetings were hosted via online videoconferences. The eDelphi exercise and consensus voting were performed using Qualtrics survey software. Participants were adults with PG, healthcare professionals, researchers and industry representatives.

Results

Collaborative discussions and systematic reviews yielded 115 items, which were distilled into 15 prospective domains. The eDelphi exercise removed the three lowest-priority domains (‘laboratory tests’, ‘treatment costs’ and ‘disease impact on family’) and ranked ‘pain’, ‘quality of life’ and ‘physical symptoms’ as the highest-priority prospective domains. Consensus was reached on the domains of ‘pain’, ‘quality of life’ and ‘clinical signs’. The domain of ‘disease course/disease progression’ narrowly failed to reach consensus for inclusion in the core set (32% of participants voted ‘no’). Refinement of this domain definition will be required and presented for consideration at future consensus meetings.

Conclusions

The UPGRADE core domain set for clinical trials in PG has been agreed by international multistakeholder consensus. Future work will develop and/or select outcome measurement instruments for these domains to establish a COS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pyoderma GangrenosumHumansClinical Trials as TopicDelphi TechniqueQuality of LifeTreatment OutcomeSystematic Reviews as Topic

Autor:innen und Institutionen

  • Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
  • Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Public Health, Infection, and Immunity, Amsterdam, the Netherlands.
  • South Shore Health Center for Wound Healing, Weymouth, MA, USA.
  • Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

ORCID-Profile: Michael E Jacobson, Kim S Thomas

Zitieren

APA

Jacobson, M. E., Rick, J. W., Gerbens, L. A. A., Baghoomian, W., Gould, L. J., Marzano, A. V., Chen, D. M., Oakes, D. L., Dissemond, J., Yamamoto, T., Shinkai, K., Nolan, B., Lobato, D., Thomas, K. S., Ortega-Loayza, A. G., & UPGRADE (2024). A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad420

Vancouver

Jacobson ME, Rick JW, Gerbens LAA, Baghoomian W, Gould LJ, Marzano AV, et al. A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad420

BibTeX
@article{Jacobson2024,
  author = {Jacobson, Michael E and Rick, Jonathan W and Gerbens, Louise A A and Baghoomian, Wenelia and Gould, Lisa J and Marzano, Angelo V and Chen, Diana M and Oakes, Debbie L and Dissemond, Joachim and Yamamoto, Toshiyuki and Shinkai, Kanade and Nolan, Barbara and Lobato, Dan and Thomas, Kim S and Ortega-Loayza, Alex G and UPGRADE, UPGRADE},
  title = {A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljad420}
}
Kostenlos starten →